ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Denosumab

Also written as “denosumab”, “CT-P41” and “AMG 162”.

Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Breast Neoplasms · Giant Cell Tumor of Bone · Prostatic Neoplasms, led by 13 companies.

Drug pageDenosumab: every studyMany companies study it; this page follows only the 78 they lead. All 207 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 20, 201278 company-led studies, 5 open or runningNext primary completion: Jan 23, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen553 open or runningphase 4since Nov 20, 2012Aug 6, 2002Jan 23, 2027phase 4 · NCT06332014
GlaxoSmithKlineits history only50 open or runningphase 3since Oct 20, 2011Oct 20, 2011none ahead
Celltrionits history only30 open or runningphase 3since Feb 12, 2021Aug 11, 2020none ahead
Mabwell (Shanghai) Bioscienceits history only30 open or runningphase 3since Jan 18, 2022Mar 12, 2021none ahead
Daiichi Sankyoits history only20 open or runningphase 3since May 16, 2008May 16, 2008none ahead
Fosun Pharmaits history only20 open or runningphase 3since Apr 23, 2022Aug 27, 2020none ahead
Shanghai Biomabs Pharmaceuticalits history only20 open or runningphase 3since Oct 15, 2020Apr 18, 2019none ahead
AryoGen Pharmedits history only10 open or runningphase 3since Sep 19, 2017Sep 19, 2017none ahead
Hamad Medicalits history only10 open or runningphase 3since Jan 22, 2017Jan 22, 2017none ahead
Lambda Therapeutic Researchits history only11 open or runningphase 3since Jun 7, 2022Jun 7, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 41 studies since Aug 6, 2002.

  1. May 31, 2013Phase 1 study in Healthy VolunteerNCT01869686 · 12 enrolled · United States
  2. Sep 24, 2013Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01951586 · 226 enrolled · United States, Australia, Canada and more
  3. Jan 31, 2014Phase 1 study in Healthy VolunteerNCT02053753 · 146 enrolled · United States
  4. Feb 25, 2014Phase 1 study in Healthy Volunteer, Female, BreastNCT02099461 · 82 enrolled · United States
  5. Mar 12, 2014Phase 4 study in Bone DiseasesNCT02101164
  6. Jun 4, 2014Phase 3 study in Osteoporosis, PostmenopausalNCT02157948 · 394 enrolled · United States, Canada, Denmark and more
  7. Jan 28, 2015Phase 3 study in Osteogenesis ImperfectaNCT02352753 · 153 enrolled · United States, Australia, Belgium and more
  8. May 8, 2017Phase 3 study in OsteoporosisNCT03164928 · 24 enrolled · United States, Australia, Belgium and more
  9. Sep 29, 2017Phase 4 study in Giant Cell Tumor of BoneNCT03301857 · 85 enrolled · United States, Australia, France and more
  10. Jun 21, 2018Phase 3 study in Osteogenesis ImperfectaNCT03638128 · 75 enrolled · United States, Australia, Belgium and more
  11. Jan 28, 2019Phase 1 study in OsteoporosisNCT03822078 · 45 enrolled
  12. Oct 7, 2020Phase 4 study in Giant Cell Tumor of BoneNCT04586660 · 36 enrolled · China, Taiwan
  13. Mar 19, 2024Phase 4 study in OsteoporosisNCT06332014 · 102 enrolled · China
  14. Sep 5, 2024Phase 4 study in Glucocorticoid-induced OsteoporosisNCT06588153 · 102 enrolled · China

Ahead

  1. Jan 23, 2027Primary completion: phase 4 study in OsteoporosisNCT06332014
  2. Apr 27, 2027Primary completion: phase 4 study in Glucocorticoid-induced OsteoporosisNCT06588153
  3. Mar 7, 2028Primary completion: phase 4 study in Giant Cell Tumor of BoneNCT04586660

TargetBeta

TNFSF11 →read by rule
“A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity”NCIt, by rule
“Tumor necrosis factor ligand superfamily member 11 inhibitor”ChEMBL 37, by rule

Other programs on TNFSF11

ProgramCompanyFurthest phaseStudies
QL1206ruleQilu Pharmaceuticalphase 35
SHR-2017Jiangsu HengRui Medicinephase 12

Studies

All 55 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06588153Glucocorticoid-induced Osteoporosis · China4Active, not recruitingApr 27, 2027102
NCT06332014Osteoporosis · China4Active, not recruitingJan 23, 2027102
NCT04586660Giant Cell Tumor of Bone · China, Taiwan4Active, not recruitingMar 7, 202836
NCT03822078Osteoporosis1CompletedDec 24, 200445
NCT03638128Osteogenesis Imperfecta · United States, Australia, Belgium and more3TerminatedMar 28, 202275
NCT03301857Giant Cell Tumor of Bone · United States, Australia, France and more4CompletedJul 27, 202385
NCT03164928Osteoporosis · United States, Australia, Belgium and more3CompletedDec 13, 202124
NCT02352753Osteogenesis Imperfecta · United States, Australia, Belgium and more3TerminatedMar 26, 2022153
NCT02157948Osteoporosis, Postmenopausal · United States, Canada, Denmark and more3CompletedJul 2015394
NCT02101164Bone Diseases4WithdrawnNov 20140
NCT02099461Healthy Volunteer, Female, Breast · United States1CompletedJul 201482
NCT02053753Healthy Volunteer · United States1CompletedAug 2014146
NCT01951586Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2CompletedJul 29, 2016226
NCT01869686Healthy Volunteer · United States1CompletedSep 201312
NCT01824342Castrate-resistant Prostate Cancer · Czech Republic, United Kingdom3CompletedFeb 201418
NCT01732770Osteoporosis, Postmenopausal · United States, Australia, Belgium and more4CompletedJan 7, 2015643
NCT01575873Steroid-induced Osteopor, Glucocorticoid-induced Ostepor · United States, Argentina, Belgium and more3CompletedJun 21, 2016795
NCT01464931Renal Insufficiency · United States1CompletedJan 201332
NCT01419717Neoplasms · Argentina, Austria, Belgium and more3CompletedAug 10, 2018129
NCT01345019Neoplasms · United States, Australia, Austria and more3CompletedJul 19, 20161,718
NCT01294397Bone Diseases, Metabolic · United States1TerminatedJan 201619
NCT01221727Osteoporosis, Postmenopausal1CompletedJul 201130
NCT01077154Breast Neoplasms · United States, Argentina, Australia and more3TerminatedAug 31, 20174,509
NCT00980174Bone Diseases, Metabolic3CompletedJun 21, 2011242
NCT00950911Multiple Myeloma · Czech Republic, United Kingdom3CompletedFeb 201235
NCT00936897Osteoporosis, Postmenopausal3CompletedNov 2011833
NCT00925600Neoplasms · United States, Australia, Bulgaria and more3CompletedMay 12, 2016769
NCT00919711Osteoporosis3CompletedDec 21, 2011870
NCT00896532Bone Diseases, Metabolic2CompletedFeb 21, 2011419
NCT00896454Breast Neoplasms · United States, Canada, France and more2CompletedSep 13, 201233
NCT00890981Bone Diseases, Metabolic3CompletedJun 201079
NCT00838201Neoplasms · United States, Canada, Finland and more3CompletedMay 3, 2012384
NCT00680992Neoplasms · United States, Australia, Austria and more2CompletedMay 17, 2018535
NCT00556374Breast Neoplasms · Austria, Sweden3CompletedOct 7, 20143,420
NCT00523341Bone Diseases, Metabolic3CompletedJul 19, 20154,550
NCT00518531Osteoporosis3CompletedJun 1, 2009250
NCT00515463Bone Diseases, Metabolic3CompletedMar 2008311
NCT00396279Giant Cell Tumor of Bone2CompletedApr 7, 200837
NCT00377819Osteoporosis, Postmenopausal3CompletedMar 2008504
NCT00330759Multiple Myeloma3CompletedApr 1, 20091,779
NCT00325468Bone Diseases, Metabolic3CompletedMar 28, 2011200
NCT00321620Fractures, Bone3CompletedOct 1, 20091,904
NCT00321464Fractures, Bone3CompletedJul 20, 20092,049
NCT00330460Osteoporosis3CompletedNov 20071,189
NCT00306189Osteoporosis2CompletedJun 2007212
NCT00293813Osteoporosis, Postmenopausal2CompletedMar 2008247
NCT00286091Hormone Refractory Prostate Cancer3CompletedJul 30, 20101,435
NCT00259740Recurrence2CompletedAug 200796
NCT00095498Arthritis, Rheumatoid2CompletedApr 1, 2007227
NCT00091832Breast Neoplasms2CompletedNov 2005255
NCT00091793Osteoporosis, Postmenopausal3CompletedFeb 2009332
NCT00089791Osteoporosis3CompletedJun 17, 20087,808
NCT00089674Prostatic Neoplasms3CompletedMay 16, 20081,468
NCT00089661Breast Neoplasms3CompletedMay 11, 2007252
NCT00043186Bone Diseases, Metabolic2CompletedApr 2007412

How it is read

Names in the registry

  • “Denosumab”, 41 entries
  • “denosumab”, 10 entries
  • “CT-P41”, 3 entries
  • “AMG 162”, 3 entries
  • “Prolia®”, 2 entries

Codes read as this program: CMAB807.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.